Economic evaluation of dasatinib in the treatment of chronic myeloid leukemia patients resistant to imatinib in Chile
Objective. Within the framework of Chronic Myelogenous Leukaemia (CML) treatment in Chile, and based on a previously performed economic evaluation, we compared the costs and cost-effectiveness ratio of using 100 mg/day and 140 mg/day doses of dasatinib with the use of 800 mg/day doses of nilotinib o...
Main Authors: | Milva Caputo, Eleonora Aiello, Juan Esteban Valencia, John Jairo Orozco Giraldo |
---|---|
Format: | Article |
Language: | English |
Published: |
Medwave Estudios Limitada
2011-04-01
|
Series: | Medwave |
Subjects: | |
Online Access: | http://dx.doi.org/10.5867/medwave.2011.04.5012 |
Similar Items
-
Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission
by: V. A. Shuvaev, et al.
Published: (2015-01-01) -
Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission
by: V. A. Shuvaev, et al.
Published: (2015-01-01) -
Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01) -
Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01) -
Debating Frontline Therapy in Chronic Myeloid Leukemia
by: Xia Bi, et al.
Published: (2021-09-01)